article thumbnail

£7M financing to drive commercialisation in cell and gene therapy 

Drug Discovery World

Using MIPs’ sophisticated and highly scalable synthetic chemistry approach means they are well positioned to benefit from this tremendous high growth opportunity.” Liz Klein, Investment Director at Calculus, added: “MIP Discovery’s synthetic affinity reagents hold huge potential to overcome bottlenecks in CGT development and production.

Therapies 130
article thumbnail

Eco-friendly enzyme to create key chemical building blocks

Science Daily: Pharmacology News

Applying this photoenzymatic approach, researchers have developed a clean, efficient way to synthesize crucial chemical building blocks known as chiral amines, solving a longstanding challenge in synthetic chemistry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Tackling pain and mental health with plant-based medicines

Drug Discovery World

This was first demonstrated in 1899 with the production of aspirin, a semi-synthetic drug based on the natural product salicin isolated from white bark (Salix alba).

article thumbnail

Part 2 Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis - Recap

The Strateos Blog: Drug Discovery

On September 15th, Strateos hosted Part 2 of its Chemistry Webinar Series: Remote Access Robotic Controlled Compound Synthesis. Ben Miles, Ph.D., Head of Product Management at Strateos was joined by Josh Bond, Director of Product Management at PerkinElmer Informatics to discuss this exciting collaboration.

article thumbnail

Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development

The Pharma Data

Kazumi holds a PhD in Synthetic Chemistry from UC Berkeley. Kazumi started her career at AbbVie (then Abbott Labs) and from there joined Millennium (now part of Takeda), where she worked in senior functions in both research and corporate development. She is also a Board member of the Sandford Burnham Prebys Institute.

article thumbnail

Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound

DrugBaron

A lot of resources are therefore poured into synthetic chemistry, and if the compound family is at all synthetically challenging it can require dozens, even hundreds, of chemists to churn out every imaginable variant.

article thumbnail

Global advances in synthetic biology

Drug Discovery World

This study is an example of computational biology, genetic sequencing, and synthetic chemistry coming together to unlock the secrets of bacterial evolution.” . “This isn’t just a cool new molecule, it’s a validation of a novel approach to drug discovery,” said Rockefeller’s Sean F Brady.